Tonix Pharmaceuticals Launches $7 Million Offering to the Public

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is thrilled to announce it has entered into an agreement to purchase and sell 7 million shares of its common stock for a combined offering price of $1 per share, along with accompanying warrants that are exercisable on the date of issuance and set to expire five years later.

This public offering is expected to close on or around August 1, 2023, barring the satisfaction of any standard closing terms. This marks an exciting opportunity for current and potential investors to join forces with Tonix to advance its biopharmaceutical industry mission and objectives.

The Company will be raising approximately $7 million through the offering, with the net proceeds intended to be used for working capital, facilities and the growth of its product portfolio. With new resources available, it can build on existing successes and continue to develop and bring to market new and innovative products that will address key industry challenges and open up new markets.

A.G.P./Alliance Global Partners has taken the helm as the lead placement agent for the upcoming offering, setting the stage for a successful launch!

Brookline Capital Markets, a subsidiary of Arcadia Securities, LLC, is proud to act as co-placement agent for an upcoming offering. We are dedicated to providing our clients with the best possible service and we ensure that this will be a successful venture.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a biopharmaceutical innovator, bringing therapeutics designed to treat and prevent human disease and alleviate suffering to market. Their range of medications for acute migraine – Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg – are indicated for adults with or without aura. Their development pipeline focuses on central nervous system (CNS), rare diseases, immunology and infectious disease product candidates.

For example, TNX-102 SL, their lead CNS candidate, is a cyclobenzaprine HCl sublingual tablet making its way towards a Phase 3 study for the management of fibromyalgia. The results of this potentially registration-enabling study are expected in the fourth quarter of 2023.

TNX-2900 is an intranasal potentiated oxytocin being developed to treat Prader-Willi syndrome, and TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) to prevent allograft rejection and treat autoimmune diseases. The firm is also developing a vaccine to prevent smallpox – TNX-801 – and small molecules to target a range of infectious diseases.

Leave a Comment